Rockwell Medical, Inc. RMTI
Biotechnology: Pharmaceutical Preparations · IPO 1998 · data as of November 13, 2026
Rockwell Medical, Inc. (RMTI) is a healthcare company listed in the US with a market value of about $28M. In the twelve months to September 30, 2026 it had revenue of $73M and net income of -$6M, a net margin of -7.8%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 33.7, 5-year revenue growth of 2% a year, a 5-year average ROIC of -33%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 29% below the current price.
About Rockwell Medical
Rockwell Medical is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 1998. Revenue went from $54M in 2014 to $69M in 2025, growth of about 2.3% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 151% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Positive free cash flow
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $73M | $69M | $101M | $84M | $73M | $62M | $62M | $61M | $63M | $57M | $53M |
| Net income | -$6M | -$5M | -$480000 | -$8M | -$19M | -$33M | -$31M | -$34M | -$32M | -$26M | -$20M |
| Free cash flow | $828000 | -$1M | $3M | -$10M | — | — | — | — | — | — | — |
| EPS (diluted) | $-0.07 | $-0.15 | $-0.03 | $-0.37 | $-1.31 | $-3.83 | $-4.51 | $-6.16 | $-6.71 | $-5.61 | $-4.29 |
| Net margin | -7.8% | -7.7% | -0.5% | -10.1% | -25.7% | -52.8% | -49.7% | -55.7% | -50.7% | -45.2% | -37.2% |
| ROIC | — | -9.7% | 1.4% | -20.6% | -48.5% | -85.9% | -39.3% | -112.0% | -94.0% | -78.8% | -30.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $20.00, 184% above the current price; targets range from $20.00 to $20.00; the consensus rating is “Strong buy”; expected EPS is $-2.12 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Rockwell Medical stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 29% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Rockwell Medical pay a dividend?
Not currently.
Is Rockwell Medical a good stock to buy?
We do not give buy or sell advice. Rockwell Medical scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.